Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line.

Trial Profile

Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms REMARC
  • Most Recent Events

    • 20 Apr 2017 Results published in the Journal of Clinical Oncology.
    • 06 Dec 2016 First analysis results of the REMARC study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Oct 2016 Data from this trial will be presented at the 2016 American Society of Hematology (ASH) annual meeting, as reported by a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top